Thyroid-Stimulating Hormone and Clinical Outcomes

被引:36
作者
Perez, Ana Cristina [1 ]
Jhund, Pardeep S. [1 ]
Stott, David J. [2 ]
Gullestad, Lars [3 ,4 ,5 ]
Cleland, John G. F. [6 ]
van Veldhuisen, Dirk J. [7 ]
Wikstrand, John [8 ]
Kjekshus, John [3 ,4 ,5 ]
McMurray, John J. V. [1 ]
机构
[1] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Glasgow G12 8TA, Lanark, Scotland
[2] Glasgow Royal Infirm, Dept Acad Geriatr Med, Glasgow G4 0SF, Lanark, Scotland
[3] Univ Oslo, Rikshosp, Oslo Univ Hosp, Dept Cardiol, N-0027 Oslo, Norway
[4] Univ Oslo, KG Jebsen Cardiac Res Ctr, Oslo, Norway
[5] Univ Oslo, Fac Med, Ctr Heart Failure Res, Oslo, Norway
[6] Hull York Med Sch, Kingston Upon Hull, Yorks, England
[7] Univ Med Ctr Groningen, Groningen, Netherlands
[8] Gothenburg Univ, Sahlgrenska Acad, Wallenberg Lab Cardiovasc Res, Gothenburg, Sweden
基金
欧盟第七框架计划;
关键词
clinical outcome; hyperthyroidism; hypothyroidism; HEART-FAILURE; NATRIURETIC PEPTIDE; ROSUVASTATIN; DISEASE;
D O I
10.1016/j.jchf.2013.07.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives This study sought to examine the association between thyroid status and clinical outcomes in patients in the CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure) study. Background Hypo-and hyperthyroidism were associated with worse clinical outcomes in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). Methods In CORONA, 4,987 patients underwent baseline thyroid-stimulating hormone (TSH) measurement, 237 of which (4.8%) were receiving thyroid replacement therapy (TRT). Patients were classified as euthyroid (TSH: 0.3 to 5.0 mu U/ml, and no TRT), hyperthyroid (<0.3 mu U/ml and no TRT), or hypothyroid (>5.0 mu U/ml and no TRT). The outcome composites of cardiovascular (CV) death or hospitalization for heart failure (HF), the components of this composite, and all-cause death were compared among hyperthyroid, hypothyroid, and euthyroid states, using multivariable models adjusting for previously reported prognostic variables. Results A total of 91.3% of patients were euthyroid, 5.0% were hypothyroid, and 3.7% were hyperthyroid. Compared with euthyroid patients, hypothyroid patients were more likely to have a history of stroke, had worse renal function and higher N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, were more likely to be treated with an antiarrhythmic drug (or have an implantable cardioverter defibrillator), and were less likely to smoke or be treated with a beta-blocker or angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. In univariate analyses, hypothyroidism was associated with an increased risk of the composite outcome of CV death or HF hospitalization (hazard ratio: 1.29; 95% confidence interval: 1.07 to 1.57; p = 0.008), as well as all-cause death (HR: 1.36; 95% confidence interval: 1.03 to 1.76; p = 0.004). However, after adjustment for other known predictors of outcome, the associations were weakened, and when NT-proBNP was added to the models, the association between hypothyroidism and all outcomes was eliminated. Conclusions Thyroid status is not an independent predictor of outcome in heart failure with reduced ejection fraction. (C) 2014 by the American College of Cardiology Foundation
引用
收藏
页码:35 / 40
页数:6
相关论文
共 10 条
[1]   Thyroid hormone metabolism in patients with congestive heart failure: The low triiodothyronine state [J].
Ascheim, DD ;
Hryniewicz, K .
THYROID, 2002, 12 (06) :511-515
[2]   Thyrotropin levels and risk of fatal coronary heart disease [J].
Asvold, Bjorn O. ;
Bjoro, Trine ;
Nilsen, Tom Ivar L. ;
Gunnell, David ;
Vatten, Lars J. .
ARCHIVES OF INTERNAL MEDICINE, 2008, 168 (08) :855-860
[3]   Prognostic impact of subclinical thyroid dysfunction in heart failure [J].
Frey, Anna ;
Kroiss, Matthias ;
Berliner, Dominik ;
Seifert, Marina ;
Allolio, Bruno ;
Gueder, Guelmisal ;
Ertl, Georg ;
Angermann, Christiane E. ;
Stoerk, Stefan ;
Fassnacht, Martin .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (01) :300-305
[4]   The role of thyroid hormone in the pathophysiology of heart failure: clinical evidence [J].
Galli, E. ;
Pingitore, A. ;
Iervasi, G. .
HEART FAILURE REVIEWS, 2010, 15 (02) :155-169
[5]   Rosuvastatin in older patients with systolic heart failure [J].
Kjekshus, John ;
Apetrei, Eduard ;
Barrios, Vivencio ;
Boehm, Michael ;
Cleland, John G. F. ;
Cornel, Jan H. ;
Dunselman, Peter ;
Fonseca, Candida ;
Goudev, Assen ;
Grande, Peer ;
Gullestad, Lars ;
Hjalmarson, Ake ;
Hradec, Jaromir ;
Janosi, Andras ;
Kamensky, Gabriel ;
Komajda, Michel ;
Korewicki, Jerzy ;
Kuusi, Timo ;
Mach, Francois ;
Mareev, Vyacheslav ;
McMurray, John J. V. ;
Ranjith, Naresh ;
Schaufelberger, Maria ;
Vanhaecke, Johan ;
van Veldhuisen, Dirk J. ;
Waagstein, Finn ;
Wedel, Hans ;
Wikstrand, John .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (22) :2248-2261
[6]   Thyroid disease and the heart [J].
Klein, Irwin ;
Danzi, Sara .
CIRCULATION, 2007, 116 (15) :1725-1735
[7]   Thyroid Function in Heart Failure and Impact on Mortality [J].
Mitchell, Judith E. ;
Hellkamp, Anne S. ;
Mark, Daniel B. ;
Anderson, Jill ;
Johnson, George W. ;
Poole, Jeanne E. ;
Lee, Kerry L. ;
Bardy, Gust H. .
JACC-HEART FAILURE, 2013, 1 (01) :48-55
[8]  
Opasich C, 1996, EUR HEART J, V17, P1860
[9]   N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states [J].
Schultz, M ;
Faber, J ;
Kistorp, C ;
Jarlov, A ;
Pedersen, F ;
Wiinberg, N ;
Hildebrandt, P .
CLINICAL ENDOCRINOLOGY, 2004, 60 (01) :54-59
[10]   Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide [J].
Wedel, Hans ;
McMurray, John J. V. ;
Lindberg, Magnus ;
Wikstrand, John ;
Cleland, John G. F. ;
Cornel, Jan H. ;
Dunselman, Peter ;
Hjalmarson, Ake ;
Kjekshus, John ;
Komajda, Michel ;
Kuusi, Timo ;
Vanhaecke, Johan ;
Waagstein, Finn .
EUROPEAN JOURNAL OF HEART FAILURE, 2009, 11 (03) :281-291